These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 10815906)
1. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Haitel A; Wiener HG; Baethge U; Marberger M; Susani M Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906 [TBL] [Abstract][Full Text] [Related]
2. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509 [TBL] [Abstract][Full Text] [Related]
3. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Hashimoto H; Sue Y; Saga Y; Tokumitsu M; Yachiku S Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685 [TBL] [Abstract][Full Text] [Related]
4. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436 [TBL] [Abstract][Full Text] [Related]
5. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343 [TBL] [Abstract][Full Text] [Related]
6. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index]. Xu QZ; Liu F; Lu DH; Yu SZ; Yang H Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073 [TBL] [Abstract][Full Text] [Related]
7. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660 [TBL] [Abstract][Full Text] [Related]
8. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282 [TBL] [Abstract][Full Text] [Related]
9. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Würl P; Meye A; Schmidt H; Lautenschläger C; Kalthoff H; Rath FW; Taubert H Oncogene; 1998 Mar; 16(9):1183-5. PubMed ID: 9528860 [TBL] [Abstract][Full Text] [Related]
10. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience. Abolhasani M; Salarinejad S; Asgari M Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638 [TBL] [Abstract][Full Text] [Related]
11. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas. Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361 [TBL] [Abstract][Full Text] [Related]
12. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045 [TBL] [Abstract][Full Text] [Related]
13. Selected morphologic features influencing the prognosis of conventional renal cell carcinomas co-expressing P53 and MDM2. Hejnold M; Dyduch G; Białas M; Demczuk S; Ryś J; Szopiński T; Chłosta P; Okoń K Pol J Pathol; 2014 Mar; 65(1):29-33. PubMed ID: 25119006 [TBL] [Abstract][Full Text] [Related]
14. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival. Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716 [TBL] [Abstract][Full Text] [Related]
15. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450 [TBL] [Abstract][Full Text] [Related]
16. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753 [TBL] [Abstract][Full Text] [Related]
17. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Kersemaekers AM; Fleuren GJ; Kenter GG; Van den Broek LJ; Uljee SM; Hermans J; Van de Vijver MJ Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709 [TBL] [Abstract][Full Text] [Related]
18. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476 [TBL] [Abstract][Full Text] [Related]
19. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer. Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716 [TBL] [Abstract][Full Text] [Related]
20. In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases. Emanuels AG; Koudstaal J; Burger MP; Hollema H Br J Cancer; 1999 Apr; 80(1-2):38-43. PubMed ID: 10389975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]